1-9 of 9
Martino Introna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy

Free
Josée Golay, Anna D’Amico, Gianmaria Borleri, Michela Bonzi, Rut Valgardsdottir, Rachele Alzani, Sabrina Cribioli, Clara Albanese, Enrico Pesenti, Maria Chiara Finazzi, Giulia Quaresmini, Dirk Nagorsen, Martino Introna, Alessandro Rambaldi
Journal: The Journal of Immunology
J Immunol (2014) 193 (9): 4739–4747.
https://doi.org/10.4049/jimmunol.1401550
Published: 01 November 2014
View articletitled, A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
Open the PDF for A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy in another window
Add to Citation Manager for A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
Includes: Supplementary data
Journal Articles

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

Free
Luca Bologna, Elisa Gotti, Fabio Da Roit, Tamara Intermesoli, Alessandro Rambaldi, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2013) 190 (1): 231–239.
https://doi.org/10.4049/jimmunol.1202645
Published: 01 January 2013
View articletitled, Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Open the PDF for Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy in another window
Add to Citation Manager for Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Includes: Supplementary data
Journal Articles

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Free
Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2011) 186 (6): 3762–3769.
https://doi.org/10.4049/jimmunol.1000303
Published: 15 March 2011
View articletitled, Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Open the PDF for Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab in another window
Add to Citation Manager for Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Includes: Supplementary data
Journal Articles

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

Free
Marzia Leidi, Elisa Gotti, Luca Bologna, Elena Miranda, Monica Rimoldi, Antonio Sica, Massimo Roncalli, Giuseppe A. Palumbo, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2009) 182 (7): 4415–4422.
https://doi.org/10.4049/jimmunol.0713732
Published: 01 April 2009
View articletitled, M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Open the PDF for M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro in another window
Add to Citation Manager for M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Journal Articles

The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab

Free
Elena Cittera, Marzia Leidi, Chiara Buracchi, Fabio Pasqualini, Silvano Sozzani, Annunciata Vecchi, J. Douglas Waterfield, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2007) 178 (10): 6616–6623.
https://doi.org/10.4049/jimmunol.178.10.6616
Published: 15 May 2007
View articletitled, The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab
Open the PDF for The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab in another window
Add to Citation Manager for The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab
Journal Articles

Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program

Free
Marcello Chieppa, Giancarlo Bianchi, Andrea Doni, Annalisa Del Prete, Marina Sironi, Gordana Laskarin, Paolo Monti, Lorenzo Piemonti, Andrea Biondi, Alberto Mantovani, Martino Introna, Paola Allavena
Journal: The Journal of Immunology
J Immunol (2003) 171 (9): 4552–4560.
https://doi.org/10.4049/jimmunol.171.9.4552
Published: 01 November 2003
View articletitled, Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program
Open the PDF for Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program in another window
Add to Citation Manager for Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program
Journal Articles

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

Free
Nicola Di Gaetano, Elena Cittera, Rachele Nota, Annunciata Vecchi, Valeria Grieco, Eugenio Scanziani, Marina Botto, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2003) 171 (3): 1581–1587.
https://doi.org/10.4049/jimmunol.171.3.1581
Published: 01 August 2003
View articletitled, Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Open the PDF for Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo in another window
Add to Citation Manager for Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Journal Articles

Bacterial Lipopolysaccharide Causes Rapid Shedding, Followed by Inhibition of mRNA Expression, of the IL-1 Type II Receptor, with Concomitant Up-Regulation of the Type I Receptor and Induction of Incompletely Spliced Transcripts

Free
Giselle Penton-Rol, Simone Orlando, Nadia Polentarutti, Sergio Bernasconi, Marta Muzio, Martino Introna, Alberto Mantovani
Journal: The Journal of Immunology
J Immunol (1999) 162 (5): 2931–2938.
https://doi.org/10.4049/jimmunol.162.5.2931
Published: 01 March 1999
View articletitled, Bacterial Lipopolysaccharide Causes Rapid Shedding, Followed by Inhibition of mRNA Expression, of the IL-1 Type II Receptor, with Concomitant Up-Regulation of the Type I Receptor and Induction of Incompletely Spliced Transcripts
Open the PDF for Bacterial Lipopolysaccharide Causes Rapid Shedding, Followed by Inhibition of mRNA Expression, of the IL-1 Type II Receptor, with Concomitant Up-Regulation of the Type I Receptor and Induction of Incompletely Spliced Transcripts in another window
Add to Citation Manager for Bacterial Lipopolysaccharide Causes Rapid Shedding, Followed by Inhibition of mRNA Expression, of the IL-1 Type II Receptor, with Concomitant Up-Regulation of the Type I Receptor and Induction of Incompletely Spliced Transcripts
Journal Articles

The A-Myb Transcription Factor Is a Marker of Centroblasts In Vivo

Free
Josée Golay, Vania Broccoli, Giuseppe Lamorte, Carlo Bifulco, Carlo Parravicini, Arnold Pizzey, N. Shaun B. Thomas, Domenico Delia, Paola Ferrauti, Domenico Vitolo, Martino Introna
Journal: The Journal of Immunology
J Immunol (1998) 160 (6): 2786–2793.
https://doi.org/10.4049/jimmunol.160.6.2786
Published: 15 March 1998
View articletitled, The A-Myb Transcription Factor Is a Marker of Centroblasts In Vivo
Open the PDF for The A-Myb Transcription Factor Is a Marker of Centroblasts In Vivo in another window
Add to Citation Manager for The A-Myb Transcription Factor Is a Marker of Centroblasts In Vivo